OpenLegislation

Paragraph 15 I1

United Kingdom

(1)

Schedule 2 is amended as follows.

(2)

In the Schedule heading, for “fee” substitute “ fees and standalone MRL application fees ”.

(3)

After the Schedule heading insert the paragraph heading “ Fees for import tolerances ”.

(4)

The existing content of the Schedule (after the Schedule heading) becomes paragraph 1.

(5)

In that paragraph—

F1(a)

in the first sentence, for the words from the start to “product-related applications” substitute “Fees chargeable by a Great Britain competent authority for import tolerances”;

(b)

in the table, before item 1 insert—

“

A1Preliminary consideration of an application to determine whether the application can proceed further229
A2Co-ordination of applications1,872

”

(c)

in the notes following the table—

(i)

for note (1) substitute—

“(1)

This category is mainly for active substances not currently approved in respect of the part of F2Great Britain to which the application relates. In certain cases it may also include active substances still being reviewed if toxicological endpoints have not yet been agreed and accepted in respect of that part of Great Britain.”;

(ii)

in note (2)—

(aa)

for “plant protection products” substitute “ active substances ”;

(bb)

for “at a European level” substitute “ and accepted in respect of the part of F3Great Britain to which the application relates ”;

(iii)

in note (3)—

(aa)

for “plant protection products” substitute “ active substances ”;

(bb)

for “at European level” substitute “ and accepted in respect of the part of F4Great Britain to which the application relates ”;

(iv)

after note (3) insert—

“Fees for multiple import tolerances for the same active substance are calculated on a modular basis with a charge applied for each crop.”

(6)

After that paragraph insert—

“Fees for standalone MRL applications

2

Fees F5chargeable by a Great Britain competent authority for standalone MRL applications are in accordance with the following table.

ItemCategoryFee (£)
1Preliminary consideration of an application to determine whether the application can proceed further229
2Co-ordination of applications1,872
3Full human health description(1)16,224
4Metabolism and residues evaluation(2)6,760
5Residues evaluation(3)2,028

Notes

(1)

This category is mainly for active substances not currently approved in respect of the part of F6Great Britain to which the application relates. In certain cases it may also include active substances still being reviewed if toxicological endpoints have not yet been agreed and accepted in respect of that part of Great Britain.

(2)

This category is for active substances where toxicological endpoints have already been agreed and accepted in respect of the part of Great Britain to which the application relates but the residue definition has only been established for crop groups unrelated to the intended use.

(3)

This category is for active substances where relevant toxicological endpoints and residue definition have already been agreed and accepted in respect of the part of Great Britain to which the application relates.

Fees for multiple standalone applications for the same active substance are calculated on a modular basis with a charge applied for each crop or combination of maximum residue levels.”

Annotations

Textual amendments

F1

Sch. 1 para. 15(5)(a) substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(a)

F2

Words in Sch. 1 para. 15(5)(c)(i) substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(b)(i)

F3

Words in Sch. 1 para. 15(5)(c)(ii)(bb) substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(b)(ii)

F4

Words in Sch. 1 para. 15(5)(c)(iii)(bb) substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(b)(ii)

F5

Words in Sch. 1 para. 15(6) inserted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(3)(a)

F6

Words in Sch. 1 para. 15(6) substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(3)(b)

Commencement

I1

Sch. 1 para. 15 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1(2)